Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

2.

Does metronidazole interact with CYP3A substrates by inhibiting their metabolism through this metabolic pathway? Or should other mechanisms be considered?

Roedler R, Neuhauser MM, Penzak SR.

Ann Pharmacother. 2007 Apr;41(4):653-8. Review. Erratum in: Ann Pharmacother. 2007 May;41(5):903.

PMID:
17374625
3.

A critical analysis of the interplay between cytochrome P450 3A and P-glycoprotein: recent insights from knockout and transgenic mice.

van Waterschoot RA, Schinkel AH.

Pharmacol Rev. 2011 Jun;63(2):390-410. doi: 10.1124/pr.110.002584. Review.

4.

Deconvoluting the effects of P-glycoprotein on intestinal CYP3A: a major challenge.

Knight B, Troutman M, Thakker DR.

Curr Opin Pharmacol. 2006 Oct;6(5):528-32. Review.

PMID:
16899406
5.

Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data.

Benet LZ, Cummins CL, Wu CY.

Curr Drug Metab. 2003 Oct;4(5):393-8. Review.

PMID:
14529371
6.

In silico, in vitro and in situ models to assess interplay between CYP3A and P-gp.

Mudra DR, Desino KE, Desai PV.

Curr Drug Metab. 2011 Oct;12(8):750-73. Review.

PMID:
21568936
7.

Transport proteins and intestinal metabolism: P-glycoprotein and cytochrome P4503A.

Christians U.

Ther Drug Monit. 2004 Apr;26(2):104-6. Review.

PMID:
15228147
8.

Functional interactions between P-glycoprotein and CYP3A in drug metabolism.

Christians U, Schmitz V, Haschke M.

Expert Opin Drug Metab Toxicol. 2005 Dec;1(4):641-54. Review.

PMID:
16863430
9.

Unmasking the dynamic interplay between efflux transporters and metabolic enzymes.

Benet LZ, Cummins CL, Wu CY.

Int J Pharm. 2004 Jun 11;277(1-2):3-9. Review.

PMID:
15158963
10.

Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity?

Kirwan C, MacPhee I, Philips B.

Expert Opin Drug Metab Toxicol. 2010 Jun;6(6):761-71. doi: 10.1517/17425255.2010.482929. Review.

PMID:
20402562
11.

Pharmacokinetic and pharmacodynamic implications of P-glycoprotein modulation.

Matheny CJ, Lamb MW, Brouwer KR, Pollack GM.

Pharmacotherapy. 2001 Jul;21(7):778-96. Review.

PMID:
11444575
12.

Factors affecting the expression and function of P-glycoprotein in rats: drug treatments and diseased states.

Murakami T, Yumoto R, Nagai J, Takano M.

Pharmazie. 2002 Feb;57(2):102-7. Review.

PMID:
11878184
13.

Dietary regulation of P-gp function and expression.

Zhang W, Han Y, Lim SL, Lim LY.

Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):789-801. doi: 10.1517/17425250902997967. Review.

PMID:
19545213
14.

Psychotropic drug-drug interactions involving P-glycoprotein.

Akamine Y, Yasui-Furukori N, Ieiri I, Uno T.

CNS Drugs. 2012 Nov;26(11):959-73. doi: 10.1007/s40263-012-0008-z. Review.

PMID:
23023659
15.

Species differences in in vitro and in vivo small intestinal metabolism of CYP3A substrates.

Komura H, Iwaki M.

J Pharm Sci. 2008 May;97(5):1775-800. Review.

PMID:
17853429
16.

[Effect of intestinal cytochrome P450 3A on phytochemical presystemic metabolism].

Xia F, Chen XY.

Chin J Integr Med. 2005 Sep;11(3):232-6. Review. Chinese.

PMID:
16181542
17.
18.

Ambient tonicity and intestinal cytochrome CYP3A.

Chuang AI, Ito S.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):883-93. doi: 10.1517/17425251003781912. Review.

PMID:
20374039
19.

[Role of Scaffold Proteins in Functional Alteration of Small Intestinal P-glycoprotein by Anti-cancer Drugs].

Kobori T, Harada S, Nakamoto K, Tokuyama S.

Yakugaku Zasshi. 2015;135(5):687-95. doi: 10.1248/yakushi.14-00234-1. Review. Japanese.

20.

Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein.

Cummins CL, Wu CY, Benet LZ.

Clin Pharmacol Ther. 2002 Nov;72(5):474-89. Review. No abstract available.

PMID:
12426511
Items per page

Supplemental Content

Support Center